T-cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival
Overview
Authors
Affiliations
Purpose: Aberrant expression of T-cell coregulatory molecules has been investigated as a mechanism by which certain cancers may evade host immune surveillance. We evaluated expression of the T-cell coregulators B7-H1, B7-H3, and PD-1 in urothelial cell carcinoma (UCC) of the bladder.
Experimental Design: Immunohistochemistry for B7-H1, B7-H3, and PD-1 was done on paraffin-embedded sections from 318 consecutive patients with UCC who underwent radical cystectomy. Expression was correlated with clinicopathologic outcomes and postoperative survival.
Results: B7-H3 was widely expressed in UCC, as 222 of 314 (70.7%) tumors showed positive staining. Expression of B7-H3 in UCC was significantly increased compared with adjacent, nontumor urothelium, as a median of 70% of tumor cells expressed B7-H3, compared with 20% of cells in nontumor specimens (P < 0.001). The increase in B7-H3 expression was independent of tumor stage (P = 0.13). Expression of B7-H1 by UCC tumors (P < 0.001) and PD-1 by tumor-infiltrating lymphocytes (P = 0.012) were significantly associated with increased pathologic stage. Patients who had received intravesical bacillus Calmette-Guerin before cystectomy tended to show increased expression of B7-H3 (P = 0.023) and PD-1 (P = 0.071) but were less likely to express B7-H1 (P = 0.027). Moreover, for the subset of patients with organ-confined disease (n = 167), B7-H1 expression independently predicted all-cause mortality after cystectomy (hazard ratio, 3.18; 95% confidence interval, 1.74-5.79; P < 0.001).
Conclusions: B7-H3 is highly expressed in UCC across tumor stages, whereas B7-H1 and PD-1 expression are associated with advanced disease. B7-H1 expression predicts mortality after cystectomy for patients with organ-confined tumors. These molecules may represent novel diagnostic or prognostic markers, as well as therapeutic targets, for patients with UCC.
de Jong F, Kvikstad V, Hoedemaeker R, van der Made A, van der Bosch T, van Casteren N World J Urol. 2025; 43(1):57.
PMID: 39752014 PMC: 11698758. DOI: 10.1007/s00345-024-05392-5.
Role of B7-H3 in predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Deol E, Nabavizadeh R, Lavoie R, Dumbrava M, Horjeti E, Thapa P BJUI Compass. 2024; 5(11):1052-1058.
PMID: 39539559 PMC: 11557263. DOI: 10.1002/bco2.418.
Taylor C, Patterson K, Friedman D, Bacot S, Feldman G, Wang T Cancers (Basel). 2024; 16(17).
PMID: 39272928 PMC: 11393896. DOI: 10.3390/cancers16173071.
Singh A, Kumari M, Haldar D, Kumari Sr R, Ranjan N, Prasad R Cureus. 2024; 16(6):e62567.
PMID: 39027756 PMC: 11255390. DOI: 10.7759/cureus.62567.
The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers.
Seema Mustafa , Jansen C, Jani Y, Evans S, Zhuang T, Brown J Biomark Insights. 2024; 19:11772719241254179.
PMID: 38827239 PMC: 11143877. DOI: 10.1177/11772719241254179.